Evidence map›Paper›PMID 40836984›Full record

ArticleFrontiers in drug delivery2024

Preclinical evaluation of a novel antibiotic-eluting BioEnvelope for CIED infection prevention.

Zerelda Esquer Garrigos, John N Catanzaro, Daniel Deegan, Ji Zhang, M Rizwan Sohail

Abstract read
In one paragraph

Article in Frontiers in drug delivery, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Zerelda Esquer GarrigosDivision of Infectious Diseases, Department of Medicine, University of Mississippi Medical Center, Jackson, MS, United States.
John N CatanzaroEast Carolina Heart Institute at ECU Health Medical Center, Greenville, IL, United States.
Daniel DeeganElutia Inc, Silver Spring, MD, United States.
Ji ZhangElutia Inc, Silver Spring, MD, United States.
M Rizwan SohailSection of Infectious Diseases, Department of Medicine, Baylor College of Medicine, Houston, TX, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The risk of infection remains a significant concern with cardiovascular implantable electronic devices, necessitating the development of new strategies. This study explores the efficacy of a novel antibiotic-eluting biologic envelope designed to mitigate infection risk through localized antibiotic delivery while preserving the regenerative properties of biological matrix. Antibiotics, rifampin and minocycline, are released through polymer discs, ensuring extended drug release. Utilizing an established model of infection in a New Zealand White rabbit, the study assessed performance against Gram-positive bacterial strains, including common pathogens such as

Indexed as

antibacterial envelopebiologic envelopebiomaterial-supported drug deliverycardiac implantable device envelopeCIEDminocyclinerifampin

Identifiers

PMID40836984
PMCPMC12363317

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.